Path: utzoo!utgpu!water!watmath!uunet!ig!cunyvm.cuny.edu!CZJ%NIHCU.BITNET
From: CZJ%NIHCU.BITNET@CUNYVM.CUNY.EDU
Newsgroups: bionet.sci-resources
Subject: (none)
Message-ID: <8806250206.AA17394@presto.ig.com>
Date: 25 Jun 88 01:03:43 GMT
Sender: daemon@presto.ig.com
Lines: 364

Attached is the Table of Contents and items of interest from the
NIH Guide to Grants and Contracts 6/24/88.

Jim Cassatt






Vol. 17, No. 21, June 24, 1988


                                   NOTICES


NOTICE:  EXPANSION OF THE FLORIDA DEMONSTRATION PROJECT ....(84/138)........ 1
National Institutes of Health
Index:  NATIONAL INSTITUTES OF HEALTH


                     DATED ANNOUNCEMENTS (RFPs AND RFAs)


PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS
DEVELOPED FOR AIDS AND RELATED ILLNESSES (RFP) .............(144/209)....... 1
National Cancer Institute
Index:  CANCER


ALVEOLAR MACROPHAGES AND DEFENSE OF THE LUNG IN AIDS (RFA) ..(212/252)...... 2
National Heart, Lung, and Blood Institute                    (484/933)
Index:  HEART, LUNG, AND BLOOD


                        ONGOING PROGRAM ANNOUNCEMENTS


MINORITY INVESTIGATOR RESEARCH SUPPLEMENT (PA) ..............(258/449)...... 3
National Heart, Lung, and Blood Institute
Index:  HEART, LUNG, AND BLOOD






NOTICE:  EXPANSION OF THE FLORIDA DEMONSTRATION PROJECT

P.T. 34; K.W. 1014002

National Institutes of Health

The Office of Management and Budget (OMB) has approved the expansion of the
current Florida Demonstration Project to reduce unnecessary administrative
burden on sponsored research.  This project has enjoyed considerable success
among ten universities in the State of Florida and five Federal agencies, the
National Institutes of Health, the National Science Foundation, the Department
of Energy, the Office of Naval Research, and the U. S. Department of
Agriculture.

The OMB approval authorizes agencies to make routine use of the most
successful Florida Demonstration Project procedures in grant supported
research.  Administrative features such as post-award prior approvals,
automatic carryover of funds, no-cost extensions, and pre-award costs will be
implemented as standard provisions on a significant number of research grant
mechanisms.

The OMB approval to expand the Demonstration permits the selection of
additional institutions nationwide, as well as encourages the participation of
additional Federal agencies.  A Notice in the Federal Register, (beginning
page 20,697), June 6, 1988, explains the scope of Phase II of the
Demonstration and describes the process for selecting additional institutions.
Phase II will have the following basic purposes for both research grants and
contracts:

     To define and test further certain features of the Florida
     Demonstration Project.

     To identify and test or review new features.

     To serve as the basis for the continued development of a model
     policy for the administration of all fundamental research and
     related awards.

     To serve as a catalyst for awardee organizations and state
     government participation in reducing unnecessary or redundant
     internal and state systems administrative burden.

     To examine the potential effects of administrative requirements on
     research productivity and/or costs.

The ten institutions in the State of Florida may elect to continue to
participate in Phase II as well as five other institutions that have
participated in ancillary studies.  An additional ten to fifteen participants
may be selected on a nationally competitive basis as outlined in the Federal
register.  Participation is limited for the sake of demonstration and
evaluation.  Phase II of the Demonstration will begin on October 1, 1988.
This Demonstration will result in further improvements in sponsored programs
which will enhance research productivity and cost effectiveness.

For further information, see the Notice in the Federal Register, June 6, 1988.


                     DATED ANNOUNCEMENTS (RFPs AND RFAs)


PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS DEVELOPED FOR AIDS AND
RELATED ILLNESSES

RFP AVAILABLE:  NCI-CM-97574-29

P.T. 34; K.W. 0710100, 1007009, 0715120, 0740020

National Cancer Institute

The Developmental Therapeutics Program of the National Cancer Institute is
seeking organizations to carry out Pharmacology and Toxicology studies, the
data from which must be suitable for filing with the Food and Drug
Administration as part of Investigational New Drug Applications.  The
organizations should have the facilities and staff to carry out such studies
and the management expertise to analyze and evaluate the data.

                   Vol. 17, No. 21, June 24, 1988 - Page 1
As a mininum requirement, the contractors must perform all toxicology studies
in accord with the FDA's current Good Laboratory Practice Regulations (GLPs).
Multiple contracts will be awarded and each will be administered on a
task-managed basis.  Task orders will be issued under the "funded
cost-reimbursement level-of-effort" contracts resulting from this
solicitation.  Assignments are estimated to involved four to six chemical
agents annually.  The objectives of the task orders to be issued are:

     Validation of analytical methodology to quantitate drug plasma
     levels in laboratory animals and to measure levels in rodents and
     dogs treated with the agent under study.

     Determination of bioavailability of drug after parenteral and/or
     oral administration.

     Assessment of acute and subacute toxicity in rodents and dogs.

The principal investigator should have a doctoral degree in
pharmacology/toxicology plus at least three years of experience in directing,
implementing and evaluating drug toxicity studies in experimental animals.
The pathologist and analytical chemist should likewise have credentials which
illustrate their competence and accomplishments in serving as critical team
members in the conduct of such studies.

The government anticipates three awards on an incrementally funded basis.
Each increment will be for one year and the total contract will be awarded for
a three-year period on or about April 30, 1989.

It is anticipated that contracts to be awarded will cover a period of three
(3) years and will be incrementally funded.  The solicitation represents a
recompetition of work done under contracts currently held by Battelle Memorial
Institute, Hazleton Laboratories America, and Midwest Research Institute.  All
responsible sources may submit a proposal which will be considered by the
National Cancer Institute.

This is not a Request for Proposal (RFP).  It is anticipated that RFP number
NCI-CM-97574-29 for the above describe work will be available to interested
offerors on or about June 24, 1988, with a closing date for receipt of
proposals on August 9, 1988.  Copies of the RFP may be obtained by written
request to:

Clyde Williams
Contracting Officer
Treatment Contracts Section
Research Contracts Branch
National Cancer Institute, NIH
Blair Building, Room 224
Bethesda, Maryland  20892
Telephone:  (301) 427-8737
MINORITY INVESTIGATOR RESEARCH SUPPLEMENT

P.T. 34, FF; K.W. 0710030, 0705015, 0715040, 0715165, 0785070

National Heart, Lung, and Blood Institute

INTRODUCTION

The purpose of this announcement is to encourage minority investigators to
pursue careers in heart, lung, or blood research by providing supplemental
funds to ongoing research grants supported by NHLBI.

DESCRIPTION

The National Heart, Lung, and Blood Institute (NHLBI) will provide support for
members of ethnic minorities underrepresented in biomedical or behavioral
research through the Minority Investigator Research Supplement program.  This
supplement addresses the recruitment of eligible individuals from the full
spectrum of ethnic minorities, but with a special emphasis on Blacks,
Hispanics, and Native Americans.

Principal investigators who are supported by NHLBI research grants (including
R01s, R10s, R18s, R37s, P01s, P50s, P60s and U01s) and who are interested in
including underrepresented minority investigators in ongoing research may
submit a request for an administrative supplement for this purpose.

ELIGIBILITY

Any principal investigator with an active R01, R10, R18, R37, PO1, P50, P60,
or U01 grant from NHLBI that has a minimum of two years of research support
remaining at the time of a supplemental award is eligible to submit a request
for an administrative supplement for the purpose of recruiting a minority
investigator to work on the research grant.

A. Minority Investigator - A minority investigator is defined as an individual
from an ethnic minority underrepresented in biomedical or behavioral sciences.
The minority investigator may be affiliated with the applicant institution or
with another nearby institution.  The program is intended for the M.D. or
Ph.D. who is generally at the junior faculty level, instructor or assistant
professor, with at least one year postdoctoral research experience, but who
has not received previous funding from NIH as an independent investigator.
The minority investigator must be a U.S. citizen, a noncitizen national or
permanent resident of the U.S. at the time of application, and must make at
least a two year commitment to spend a minimum of 30 percent time on research
supported by the parent grant.  This supplement is not intended to support
summer-only research.

B. Research Experience - The proposed research experience for the minority
investigator must be part of the ongoing research of the parent grant.  When
an award is issued, there should be at least two years of research support
remaining on the parent grant.  As part of this research experience the
minority investigator should have the opportunity to interact with
investigators on the parent grant, should be able to contribute intellectually
to the research, and should have the opportunity to enhance his/her research
skills.

PROVISIONS

In order to receive a Minority Investigator Research Supplement there must be,
at the time of the supplemental award, a minimum of two years future support
remaining on the parent grant.  In the first budget period, funds will be

                   Vol. 17, No. 21, June 24, 1988 - Page 3
provided as an administrative supplement to the ongoing research grant.  In
future budget periods, funds for the minority supplement will be included in
the award to the parent grant.  Each annual supplemental budget should not
exceed $30,000 in direct costs, limited to salary, supplies, and travel, and
may not include equipment.  The continuation of support for the minority
supplement in subsequent years of the grant will depend on a satisfactory
review of progress made, research proposed for the next budget period, and the
budget.  A separate minority supplement progress report and budget page is to
be submitted as part of the noncompeting continuation application of the
principal investigator.  Funding for the supplement always is contingent on
funding of the parent grant, and cannot extend beyond the project period of
the parent grant.  Supplemental awards under this program are for the sole
purpose of supporting the research experience of the minority investigator.  A
minority investigator may receive support under this program on only one
grant.  The support should be for a minimum of two years duration, and each
parent grant can have only one minority investigator at a time.  Funds are not
transferable to another minority investigator.  Simultaneous or overlapping
Minority Investigator Research Supplements will not be considered.

The funding of this administrative supplement does not preclude the subsequent
submission of applications for career development awards (K series) or
investigator-initiated research grants by the minority investigator, or
receipt of research support.  A minority investigator who previously received
a K series award, or an investigator-initiated research project grant from NIH
is not eligible to apply for this award.

REVIEW CRITERIA

The research training committees composed of staff from the heart, lung, and
blood programs will review requests for supplemental support under this
announcement using the following criteria:

  o  Prior research training and experience of the minority
     investigator,

  o  Plans for the proposed research experience in the supplemental
     request and its relationship to the parent grant, and

  o  Assurance from the principal investigator that the experience will
     enhance the research potential and skills of the minority
     investigator.

APPLICATION PROCEDURES

The principal investigator of the parent grant should submit a request for
supplemental funds directly to the NHLBI program division that supports the
parent grant.  The request should include the following:  1) a letter with the
title and grant number of the parent grant and a statement that this is a
request for a Minority Investigator Research Supplement; 2) a brief 3-4 page
description of the proposed research experience and how it will enhance the
capabilities and foster the independent research career of the minority
investigator; 3) a statement from the minority investigator outlining research
objectives and career goals; 4) a biographical sketch of the minority
investigator that includes social security number, a list of publications, and
other evidence of scientific achievement; 5) a proposed budget for the
research experience on the first year and future years budget pages from Grant
Application Form PHS 398; and 6) documentation, if applicable, that the
proposed research experience was approved by the animal welfare committee or
human subjects institutional review board of the grantee institution.  The
request must be signed by the principal investigator and the appropriate
institutional business official.  If the minority investigator is not an
employee of the grantee institution, the request also must be accompanied by
an appropriately signed letter from the institution of the minority
investigator indicating that participation at the stated level of effort is
approved.

Requests may be submitted at any time.

The original and four (4) copies of the request should be sent to the NHLBI
program division that supports the parent grant.  Division representatives
are:








                   Vol. 17, No. 21, June 24, 1988 - Page 4
Dr. George A. Hayden
Research Training and Development Branch
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Federal Building, Room 3C01
National Institutes of Health
Bethesda, Maryland  20892
Telephone:  (301) 496-1724

or

Dr. Joan M. Wolle
Prevention, Education, and Research Training Branch
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 640
National Institutes of Health
Bethesda, Maryland  20892
Telephone:  (301) 496-7668

or

Dr. Christine Parker
Program Planning and Prevention Branch
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Federal Building, Room 520
National Institutes of Health
Bethesda, Maryland  20892
Telephone:  (301) 496-4186

or

Dr. Katrina W. Johnson
Prevention and Demonstration Research Branch
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Federal Building, Room 5C10B
National Institutes of Health
Bethesda, Maryland  20892
Telephone:  (301) 496-3503

The programs of the National Heart, Lung, and Blood Institute are identified
in Catalog of Federal Domestic Assistance, number 13.837, 13.838, and 13.839.
Awards will be made under the authority of the Public Health Service Act,
Section 301 (42 USC 241) and administered under PHS grant policies and Federal
regulations, most specifically 42 CFR Part 52 and 45 CFR Part 74.  This
program is not subject to intergovernmental review requirements of Executive